Background: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of tumors. Natural killer (NK) cells can play an important role in cancer immune surveillance. The aim of this prospective observational study was to analyze peripheral blood mononuclear cells (PBMCs) in patients with advanced non-small-cell lung cancer (NSCLC) receiving ICIs in order to identify predictive factors for better survival outcomes. Methods: Forty-seven stage IV NSCLC patients were enrolled. Patients underwent baseline (T0) and longitudinal (T1) evaluations after ICIs. Peripheral immune blood cell counts were analyzed using flow cytometry. Results: Basal levels of CD3−CD56+ NK cells were higher in patients with controlled disease (DC) compared to progression disease (PD) patients (127 cells/µL vs. 27.8 cells/µL, p < 0.001). Lower NK cell values were independent prognostic factors for shorter overall survival (OS) (HR 0.992; 95% CI 0.987–0.997, p < 0.001) and progression-free survival (PFS) (HR 0.988; 95% CI 0.981–0.994, p < 0.001). During the longitudinal evaluation, CD3−CD56+ NK cells (138.1 cells/µL vs. 127 cells/µL, p = 0.025) and CD56bright NK cells (27.4 cells/µL vs. 18.1 cells/µL, p = 0.034) significantly increased in the DC group. Finally, lower values of CD3−CD56+ NK cells (28.3 cells/µL vs. 114.6 cells/µL, p = 0.004) and CD56dim NK cells (13.2 cells/µL vs. 89.4 cells/µL, p < 0.001) were found in sarcopenic patients compared to patients without sarcopenia. Conclusions: Peripheral NK cells could represent a non-invasive and useful tool to predict ICI therapy response in NSCLC patients, and the association of low NK cell levels with sarcopenia deserves even more attention in clinical evaluation.

Circulating natural killer cells as prognostic value for non-small-cell lung cancer patients treated with Immune checkpoint inhibitors: correlation with sarcopenia / Tenuta, Marta; Pandozzi, Carla; Sciarra, Francesca; Campolo, Federica; Gelibter, Alain J.; Sirgiovanni, Grazia; Cortesi, Enrico; Lenzi, Andrea; Isidori, Andrea M.; Sbardella, Emilia; Venneri, MARY ANNA. - In: CANCERS. - ISSN 2072-6694. - 15:14(2023). [10.3390/cancers15143592]

Circulating natural killer cells as prognostic value for non-small-cell lung cancer patients treated with Immune checkpoint inhibitors: correlation with sarcopenia

Marta Tenuta
Primo
;
Carla Pandozzi
Secondo
;
Francesca Sciarra;Federica Campolo;Alain J. Gelibter;Grazia Sirgiovanni;Enrico Cortesi;Andrea Lenzi;Andrea M. Isidori;Emilia Sbardella
Penultimo
;
Mary Anna Venneri
Ultimo
2023

Abstract

Background: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of tumors. Natural killer (NK) cells can play an important role in cancer immune surveillance. The aim of this prospective observational study was to analyze peripheral blood mononuclear cells (PBMCs) in patients with advanced non-small-cell lung cancer (NSCLC) receiving ICIs in order to identify predictive factors for better survival outcomes. Methods: Forty-seven stage IV NSCLC patients were enrolled. Patients underwent baseline (T0) and longitudinal (T1) evaluations after ICIs. Peripheral immune blood cell counts were analyzed using flow cytometry. Results: Basal levels of CD3−CD56+ NK cells were higher in patients with controlled disease (DC) compared to progression disease (PD) patients (127 cells/µL vs. 27.8 cells/µL, p < 0.001). Lower NK cell values were independent prognostic factors for shorter overall survival (OS) (HR 0.992; 95% CI 0.987–0.997, p < 0.001) and progression-free survival (PFS) (HR 0.988; 95% CI 0.981–0.994, p < 0.001). During the longitudinal evaluation, CD3−CD56+ NK cells (138.1 cells/µL vs. 127 cells/µL, p = 0.025) and CD56bright NK cells (27.4 cells/µL vs. 18.1 cells/µL, p = 0.034) significantly increased in the DC group. Finally, lower values of CD3−CD56+ NK cells (28.3 cells/µL vs. 114.6 cells/µL, p = 0.004) and CD56dim NK cells (13.2 cells/µL vs. 89.4 cells/µL, p < 0.001) were found in sarcopenic patients compared to patients without sarcopenia. Conclusions: Peripheral NK cells could represent a non-invasive and useful tool to predict ICI therapy response in NSCLC patients, and the association of low NK cell levels with sarcopenia deserves even more attention in clinical evaluation.
2023
immune checkpoint inhibitors (ICIs); natural killer (NK) cells; sarcopenia; peripheral blood mononuclear cells (PBMCs); lung cancer; non-small-cell lung cancer (NSCLC)
01 Pubblicazione su rivista::01a Articolo in rivista
Circulating natural killer cells as prognostic value for non-small-cell lung cancer patients treated with Immune checkpoint inhibitors: correlation with sarcopenia / Tenuta, Marta; Pandozzi, Carla; Sciarra, Francesca; Campolo, Federica; Gelibter, Alain J.; Sirgiovanni, Grazia; Cortesi, Enrico; Lenzi, Andrea; Isidori, Andrea M.; Sbardella, Emilia; Venneri, MARY ANNA. - In: CANCERS. - ISSN 2072-6694. - 15:14(2023). [10.3390/cancers15143592]
File allegati a questo prodotto
File Dimensione Formato  
Tenuta_Circulating natural killer_2023.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 2.59 MB
Formato Adobe PDF
2.59 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1684934
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact